Bellerophon to Present at Two September Investor Conferences
September 14, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer
August 11, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results
August 05, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
July 15, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16th, from 4:00-5:00 pm EDT WARREN, N.J., July ...
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
July 13, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and...
Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes
June 29, 2020 08:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and...
Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares
May 22, 2020 09:47 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering...
Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering
May 19, 2020 07:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,076,923...
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
May 18, 2020 16:03 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its common...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), (“Bellerophon” or the “Company”) a clinical-stage biotherapeutics company focused on developing...